文献速递前列腺癌

评估4Kscore在预测前列腺癌主动监测进展中的作用:独立于临床信息和PIRADS评分

Evaluating 4Kscore's role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS score.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-09-27

这项单机构、单臂、非治疗性干预试验纳入166例活检确诊前列腺癌患者,按前瞻性MRI方案主动监测48个月。基线4Kscore≥20%者确认活检时分级进展风险更高(OR=4.04),最近一次4Kscore≥20%可预测监测活检的方案进展(OR=2.61)和分级进展(OR=5.13)。

要点

  • 基线4Kscore≥20%与确认活检时分级进展风险升高相关(OR=4.04)。
  • 最近一次4Kscore≥20%可预测监测活检时的方案进展(OR=2.61)。
  • 最近一次4Kscore≥20%可预测监测活检时的分级进展(OR=5.13)。

核心结论

  • 对于接受主动监测的患者,基线4Kscore可预测确认活检时的分级进展,最近一次4Kscore可预测监测活检时的方案进展和分级进展。

研究设计与样本

  • 单机构、单臂、非治疗性干预试验,纳入166例活检确诊前列腺癌患者,2014年至2020年入组。
  • 患者按试验规定的主动监测方案接受每年多参数MRI、前列腺活检和4Kscore检测,诊断后随访48个月。

主要发现

  • 166例患者中83例(50%)按方案进展,其中41例(占全队列24.7%)为分级进展。
  • 确认活检时,调整NCCN风险和基线PIRADS评分后,基线4Kscore≥20%者较<20%者分级进展风险更高(OR=4.04,95%CI:1.05-15.59,p=0.043)。
  • 监测活检时,最近一次4Kscore≥20%显著预测方案进展(OR=2.61,95%CI:1.03-6.63,p=0.044)和分级进展(OR=5.13,95%CI:1.63-16.11,p=0.005)。

关键数值与推荐

  • 基线4Kscore≥20%对比<20%:确认活检分级进展OR=4.04(95%CI:1.05-15.59,p=0.043)。
  • 最近一次4Kscore≥20%:监测活检方案进展OR=2.61(95%CI:1.03-6.63,p=0.044)。
  • 最近一次4Kscore≥20%:监测活检分级进展OR=5.13(95%CI:1.63-16.11,p=0.005)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 4Kscore is used to aid the decision for prostate biopsy, however its role in active surveillance (AS) has not been investigated in a magnetic resonance imaging (MRI)-based protocol. Our objective was to assess the association between 4Kscore and progression in men undergoing AS on a prospective MRI-based protocol. METHODS: This was a single-institution, single-arm, non-therapeutic, interventional trial of 166 men with biopsy-confirmed prostate cancer enrolled between 2014-2020. Patients were placed on a trial-mandated AS protocol including yearly multiparametric (mp)MRI, prostate biopsy, and 4Kscore followed for 48 months after diagnosis. We analyzed protocol-defined and grade progression at confirmatory and subsequent surveillance biopsies. RESULTS: Out of 166 patients, 83 (50%) men progressed per protocol and of them 41 (24.7% of whole cohort) progressed by grade. At confirmatory biopsy, men with a baseline 4Kscore ≥ 20% had a higher risk of grade progression compared to those with 4Kscore < 20% (OR = 4.04, 95% CI: 1.05-15.59, p = 0.043) after adjusting for National Comprehensive Cancer Network (NCCN) risk and baseline PIRADS score. At surveillance biopsies, most recent 4Kscore ≥ 20% significantly predicted per protocol (OR = 2.61, 95% CI: 1.03-6.63, p = 0.044) and grade progression (OR = 5.13, 95% CI: 1.63-16.11, p = 0.005). CONCLUSIONS: For patients on AS, baseline 4Kscore predicted grade progression at confirmatory biopsy, and most recent 4Kscore predicted per-protocol and grade progression at surveillance biopsy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Hougen HY, Reis IM, Han S, et al. Evaluating 4Kscore's role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS score. Prostate Cancer Prostatic Dis. 2024. PMID: 39333697. doi:10.1038/s41391-024-00898-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。